Skip to content

The treatment of breast cancer with thermal ablation: a pilot study

The treatment of breast cancer with thermal ablation: a pilot study - THERMAC

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON48001
Enrollment
60
Registered
2019-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast neoplasms

Interventions

Ultrasound guided percutaneous RFA, MWA or cryoablation will be performed 1-2 weeks after diagnosis. Surgical resection will take place about 3 months after diagnosis. The type of surgical resection

Sponsors

Franciscus Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Woman 2. Pathologically confirmed unifocal primary invasive breast cancer, unilateral 3. A clinical T1 tumor (

Exclusion criteria

Exclusion criteria: 1. History of invasive breast cancer 2. Pregnant or nursing 3. BRCA 1 or 2 positive (if known) 4. Breast augmentation 5. Electrical devices and/or implants 6. Neoadjuvant chemotherapy 7. Triple negative tumors, Her2neu overexpression, Elston/Nottingham grade 3, lobular carcinoma 8. Allergic to local anaesthetics

Design outcomes

Secondary

MeasureTime frame
Secondary endpoints are: feasibility of the technique, predictive value of MRI for success of the treatment, the degree and type of immune response, learning curve, system usability radiologist, patient satisfaction, patient reported cosmetic outcome, observed cosmetic result (BCCT.core).

Primary

MeasureTime frame
The primary endpoint in the pilot study is the percentage of tumours with complete ablation on pathology result 2.5 months after TA.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)